申请人:Alzheimer's Institute of America
公开号:US20150352108A1
公开(公告)日:2015-12-10
The invention relates to certain amino-pyrimidine compounds which inhibit TBK1 and/or IKK epsilon and which may therefore find application in treating inflammation, cancer, septic shock and/or Primary open Angle Glaucoma (POAG).
该发明涉及某些氨基嘧啶化合物,其抑制TBK1和/或IKK epsilon,因此可能在治疗炎症、癌症、感染性休克和/或原发性开角青光眼(POAG)方面找到应用。